A company that designs drugs using artificial intelligence has named a new candidate aimed at dry age-related macular degeneration, a leading cause of vision loss with very few treatment options.
Insilico Medicine announced on August 5 the nomination of ISM9077 as a preclinical candidate for ocular diseases including dry AMD, uveitis and dry eye disease. It is the company's 32nd preclinical candidate since 2021.
